Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people need to take Mounjaro for at least 72 weeks — roughly 17 months — to reach the weight loss seen in the pivotal SURMOUNT-1 trial, which was published in the New England Journal of Medicine. That said, how long you need to be on Mounjaro depends on your treatment goals, how your body responds, and what you and your prescriber decide together. Mounjaro is a prescription-only medicine; a GPhC-registered Independent Prescriber assesses your suitability and monitors your progress throughout, there is no fixed universal treatment length.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
SURMOUNT-1 randomised 2,539 adults with obesity across a 72-week period. Participants on 15 mg tirzepatide lost an average of roughly 20–21% of their body weight by week 72. Crucially, the data showed that weight loss was still progressing at the end of the trial for many participants, not plateauing from week one. That trajectory matters when you are thinking about how long you have to take Mounjaro, because a shorter course may capture only part of the benefit available.
The trial also made clear that dose titration takes time. Treatment opens at 2.5 mg (a tolerability step designed to let your system adjust) and moves upward in 4-weekly increments guided by your prescriber. Reaching 15 mg can take around five months on its own. Anyone expecting meaningful clinical results in the first few weeks is setting the wrong clock. For a fuller sense of the week-by-week picture, our page on how long Mounjaro takes to work breaks down early versus later response.
The NICE appraisal of tirzepatide (TA1026) does not set a maximum treatment period, but it does specify a meaningful checkpoint: if you have not achieved at least 5% weight loss after six months at your highest tolerated dose, continuing should be reviewed. That review is a normal part of supervised treatment, not a failure.
Six months in, your prescriber should be looking at whether Mounjaro is doing its job. The NICE threshold (5% weight loss by that point) is a population-level signal, not a verdict on any one person. Factors like recent illness, a stalled titration, or a dose that hasn't yet reached its maintenance level can all affect where you land at the 6-month mark.
A practical habit worth building now: weigh yourself once a week, same day, same time, same scales, and keep a simple note. That record is genuinely useful when your prescriber reviews your progress. It takes under a minute and removes the guesswork from conversations about whether treatment is working.
Beyond the 6-month checkpoint, there is no upper ceiling set in the Mounjaro licence for how long treatment can run. In clinical practice, many people continue for well over a year. The question of how long you can take Mounjaro depends on ongoing clinical review, not a fixed expiry date built into the prescription.
GLP-1 and GIP receptor agonists like tirzepatide act on appetite and satiety pathways while you are taking them. When treatment ends, those effects wind down. Clinical evidence and real-world experience both show that weight can return after stopping, particularly without robust lifestyle changes in place. That is not a reason to stay on Mounjaro indefinitely regardless of clinical need; it is a reason to plan the ending properly, with your prescriber, not abruptly.
A well-managed stop involves gradual adjustment, a review of diet and activity habits, and a shared understanding of what to watch for. For a detailed look at the longer-term picture, our overview of Mounjaro treatment duration covers the post-treatment phase in more depth.
Some people do return to treatment after a break. Others transition successfully and maintain their results. Neither path is standard, both depend on the individual's health context. The NHS guidance on weight management injections underlines that these medicines work best as part of a broader, sustained approach to diet and activity.
Because Mounjaro is taken weekly and dose increases happen over months, the financial planning is inseparable from the clinical planning. A realistic treatment horizon is at least a year for most people pursuing meaningful, sustained results. Understanding that from the start helps with both budgeting and commitment. Our guide to typical weight loss with Mounjaro gives an honest view of what that investment tends to produce.
For context on the cost side, our cost and pricing overview explains what legitimate private Mounjaro treatment includes and what questions to ask any provider. At nume, treatment pricing is transparent and shown on the treatment page; every repeat order is clinically re-reviewed, with no subscriptions and no auto-renewals.
If you are weighing up your options or want to understand which treatment might suit your situation, our weight-loss overview sets out the licensed medicines available. Eligibility is confirmed at consultation, that is the right moment to ask your prescriber directly how long treatment is likely to run for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.